Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program

Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program

Background and Aim: Data on the clinical pharmacokinetics of cannabidiol (CBD) are scanty. We explored the effect of demographic and clinical variables on plasma concentrations of purified CBD in patients with Dravet (DS) and Lennox–Gastaut syndrome (LGS).Methods: The study design was an open, prosp...

Full description

Bibliographic Details
Main Authors: Manuela Contin, Susan Mohamed, Margherita Santucci, Monica Anna Maria Lodi, Emilio Russo, Oriano Mecarelli, CBD LICE Italy Study Group
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Pharmacology
Subjects:
cannabidiol
pharmacokinetics
antiseizure medication
epilepsy
Dravet syndrome
Lennox–Gastaut syndrome
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.637801/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.637801/full

Similar Items